Clinical trial

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

NCT04647526

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2021-02-25

PhasePHASE3

Study timeline

Study start (actual)2021-02-25Date precision: day

Registry last updated2026-01-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Metastatic Castration-Resistant Prostate Cancerunresolved

Interventions

[Lu-177]-PNT2002DRUG

AbirateroneDRUG · verified · RxNorm: abiraterone

EnzalutamideDRUG · verified · RxNorm: enzalutamide

Sponsors & collaborators

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Companylead sponsor

Mapped research locations

Los AngelesCalifornia, United States3 St LouisMissouri, United States3 PhiladelphiaPennsylvania, United States2 DallasTexas, United States2 TorontoOntario, Canada2 MontrealQuebec, Canada2 New YorkNew York, United States1 HoustonTexas, United States1 BaltimoreMaryland, United States1 NashvilleTennessee, United States1 LondonUnited Kingdom1 SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04647526 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.